Tranexamic Acid and Pregabalin Interaction: What Women Need to Know

What Is the Interaction Between Tranexamic Acid and Pregabalin?

The short answer: these two drugs do not interact through shared enzymes or transporters, but they can add to each other's side effects in the nervous system. Tranexamic acid works by blocking plasminogen activators, preventing fibrin clots from breaking down prematurely, and it is not metabolized by cytochrome P450 enzymes at all. Pregabalin is also not a CYP substrate. Neither drug is a significant P-glycoprotein inhibitor. Because there is no enzyme or transporter overlap, plasma concentrations of one drug are not changed by the other.

What does matter is how both drugs affect the brain at the same time.

Tranexamic Acid: How It Works in Women

Tranexamic acid (brand names Lysteda in the United States for the oral formulation, Cyklokapron for IV) is an antifibrinolytic agent. The FDA approved oral tranexamic acid 650 mg three times daily for five days per menstrual cycle specifically for heavy menstrual bleeding in women without structural or hematologic pathology. At the topical or lower-dose systemic level, it is also used off-label and in some prescription formulations for melasma, a condition that disproportionately affects women of reproductive age, particularly those on hormonal contraception or during pregnancy.

Adverse effects in the FDA label include headache (occurring in about 50% of trial participants), nasal and sinus symptoms, back pain, and abdominal discomfort. In the key phase III trial supporting Lysteda approval, dizziness occurred in roughly 2% of women. That percentage is low, but it becomes relevant when a second sedating drug enters the picture.

Pregabalin: Its Role and Risk in Women

Pregabalin (Lyrica) binds to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, reducing release of neurotransmitters including glutamate, norepinephrine, and substance P. The FDA label lists dizziness (occurring in 27-46% of patients across trials) and somnolence (16-28%) as the most common adverse effects. Women use pregabalin for fibromyalgia (where female prevalence is roughly 7:1 over males), for neuropathic pain conditions, for generalized anxiety disorder in regions where it is licensed for that indication, and for epilepsy.

Pregabalin carries DEA Schedule V classification because of its abuse and dependence potential, a risk that deserves candid mention. A 2019 analysis in BMJ found that pregabalin prescriptions in England rose by 350% between 2004 and 2017, with misuse increasingly documented.

The Pharmacodynamic Interaction Explained

The most useful way to think about this interaction is through a simple additive-sedation framework. Both drugs can produce CNS depression independently, at different rates and through different mechanisms. When taken together, the probability of a woman experiencing dizziness, impaired coordination, or cognitive slowing is higher than with either agent alone, even though neither drug changes the blood level of the other.

Consider a woman with fibromyalgia (a common indication for pregabalin) who also has heavy menstrual bleeding or perimenopausal flooding. She might reasonably be prescribed both agents at the same time. During her five-day tranexamic acid course, she is already experiencing peak bleeding and potential fatigue from blood loss. Adding even modest additional dizziness from pharmacodynamic overlap matters for her daily function and safety, including driving.

What the DDI Databases Say

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify this combination as a minor or low-severity interaction, primarily flagging the additive CNS depression potential. No dose adjustment is required by any current US guideline for either drug when they are used together. Monitoring is symptom-based: ask the woman if she feels more dizzy or sedated than usual during the overlap period.

There is no published randomized controlled trial specifically examining the tranexamic acid and pregabalin combination in women, so the interaction classification is derived from the known individual pharmacodynamic profiles of each drug. This is an evidence gap that should be named plainly: the existing data is extrapolated, not directly studied in women taking both drugs simultaneously.

CNS Sedation and Women: Why Sex Matters Here

Women metabolize several CNS-active drugs differently than men. Body composition differences (higher percent body fat on average) affect volume of distribution for lipophilic drugs. Pregabalin is not highly lipophilic, but women in pharmacokinetic studies of gabapentinoids have shown modestly higher peak plasma concentrations relative to body weight compared to men, suggesting dose-per-kg considerations may be more important in women. The FDA has acknowledged sex-based PK differences for multiple CNS drugs, most famously mandating a lower starting dose of zolpidem for women in 2013.

No equivalent sex-specific dose adjustment exists yet for pregabalin, but women should be aware that the sedation burden may be experienced more intensely than trial averages suggest, since many trials enrolled predominantly male or mixed populations.

Who Is This Combination Most Likely to Affect?

Several women's-health populations face the highest likelihood of being prescribed both drugs at the same time.

Women With Fibromyalgia and Heavy Menstrual Bleeding

Fibromyalgia affects an estimated 2-4% of the general population, with women comprising approximately 75-90% of diagnosed cases. Pregabalin is one of only three FDA-approved medications for fibromyalgia. Women with fibromyalgia also have higher rates of menstrual irregularities and reported heavy flow, which may drive a prescription for oral tranexamic acid during heavy cycles.

Perimenopausal Women

Perimenopause brings erratic hormonal fluctuations that frequently worsen menstrual bleeding. ACOG Practice Bulletin No. 136 recognizes tranexamic acid as a first-line non-hormonal option for heavy menstrual bleeding. Perimenopausal women also carry higher rates of sleep disruption, anxiety, and musculoskeletal pain, conditions for which clinicians sometimes prescribe gabapentinoids including pregabalin. The overlap window in this life stage is real.

Women With Epilepsy on Pregabalin

Women with epilepsy often have heavier menstrual bleeding due to the effects of seizure activity and some anticonvulsants on the hypothalamic-pituitary-ovarian axis. Tranexamic acid during heavy cycles is a reasonable adjunct, and the interaction profile described here applies.

Women Using Pregabalin Off-Label for Anxiety

Pregabalin is widely prescribed off-label for generalized anxiety in the United States, and anxiety disorders are more prevalent in women than men across all age groups. A woman on pregabalin for anxiety who develops heavy menstrual bleeding may receive tranexamic acid without her providers communicating about the combination.

Mechanism in Detail: CYP, P-gp, and Renal Clearance

Tranexamic acid is excreted primarily by the kidneys unchanged, with approximately 90% of an oral dose recovered in urine within 24 hours. It does not undergo significant hepatic metabolism and has no clinically meaningful effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.

Pregabalin is similarly eliminated renally with negligible hepatic metabolism, and roughly 98% of absorbed pregabalin is excreted unchanged in urine. Both drugs therefore bypass the CYP system entirely, which is why pharmacokinetic interaction is absent.

The sole shared physiological pathway is renal excretion. In a woman with significant renal impairment, both drugs accumulate, and dose reduction is required for pregabalin (and potentially for tranexamic acid in severe renal disease). Renal impairment amplifies the pharmacodynamic overlap by raising plasma concentrations of both agents simultaneously. Women with chronic kidney disease should have both prescriptions reviewed carefully against their current GFR.

Pregnancy and Lactation Safety

This section is required for any drug article on WomanRx, and it deserves detailed attention because both drugs carry distinct risks during pregnancy and breastfeeding.

Tranexamic Acid in Pregnancy

Tranexamic acid is classified as FDA Pregnancy Category B, meaning animal reproduction studies have not demonstrated fetal risk but no adequate, well-controlled studies exist in pregnant women. The drug crosses the placenta. It is used intravenously during obstetric hemorrhage and surgical delivery, and the WOMAN trial, a large randomized controlled trial, found that tranexamic acid reduced death from postpartum hemorrhage by 19% when given within three hours of bleeding onset without significantly increasing thrombotic events. That is IV use for an acute life-threatening indication.

Oral tranexamic acid for heavy menstrual bleeding or melasma is a different clinical situation. Women trying to conceive should be aware that oral tranexamic acid is typically taken during the first days of menstruation; the risk of conception occurring during a treatment cycle is low. If pregnancy is confirmed, oral tranexamic acid for elective indications like melasma should be discontinued and a clinician consulted promptly.

Pregabalin in Pregnancy

Pregabalin is FDA Pregnancy Category C, and observational data raise genuine concern. A 2022 cohort study published in Neurology found that pregabalin use in early pregnancy was associated with a 1.5-fold increased risk of major congenital malformations compared to no use. The absolute risk remains low in individual terms, but the signal is sufficient to warrant avoiding pregabalin in pregnancy unless the benefit to the woman clearly outweighs the risk, for example in refractory epilepsy with no safer alternative.

Women of reproductive age taking pregabalin should be counseled about this risk and offered reliable contraception if pregnancy is not planned. This is not optional counseling: the Lyrica prescribing information explicitly states that females of reproductive potential should use effective contraception during treatment.

Lactation

Tranexamic acid is excreted in breast milk at approximately 1% of the maternal oral dose, a low level. Short-course use (five days per cycle) is generally considered compatible with breastfeeding by most lactation specialists, though direct infant safety studies are absent.

Pregabalin is present in breast milk at concentrations that may reach 76% of maternal plasma levels in some reports. The FDA label notes that in a human lactation study, the estimated infant daily dose through breast milk was approximately 0.31 mg/kg/day, representing about 7% of the maternal weight-adjusted dose. Infant sedation and weight gain effects are theoretical concerns. A breastfeeding woman on pregabalin should monitor her infant for unusual sleepiness and discuss the risk-benefit with her prescriber.

Monitoring and Practical Counseling for Women

If you are taking pregabalin for any indication and your clinician prescribes tranexamic acid for heavy bleeding or melasma, here is what to watch for.

During the five-day tranexamic acid course:

• Note any increase in dizziness, lightheadedness, or mental cloudiness beyond your typical pregabalin baseline.
• Avoid driving or operating machinery if you feel more impaired than usual.
• Do not add alcohol during the overlap window; alcohol adds a third layer of CNS depression.
• Stay hydrated, especially during heavy menstrual bleeding, since volume depletion can worsen dizziness independently.

Tell your prescriber:

• If your dizziness is severe or you fall.
• If you are experiencing renal problems, since both drugs clear through the kidneys.
• If you are pregnant or trying to conceive, because both drugs carry pregnancy-specific guidance.
• If you are taking other CNS depressants (opioids, benzodiazepines, other gabapentinoids) because the additive sedation risk compounds further.

The Menopause Society recommends that providers managing perimenopausal heavy bleeding consider the full medication list for CNS burden before adding an antifibrinolytic agent.

Who This Combination Is Right For, and Who Should Be Cautious

Generally appropriate:

• A woman in her reproductive years or perimenopause with heavy menstrual bleeding who is stable on a therapeutic pregabalin dose and experiencing no significant baseline dizziness. Short-course oral tranexamic acid (five days per cycle) at standard dose (1,300 mg three times daily or 650 mg three times daily depending on formulation) adds low additional risk.
• A woman using low-dose topical tranexamic acid for melasma. Topical absorption is minimal and systemic pharmacodynamic overlap is negligible.

Requires more caution:

• Women with renal impairment (eGFR <50 mL/min). Both drugs accumulate, raising plasma concentrations and increasing the sedation burden.
• Women on multiple CNS depressants simultaneously. Pregabalin plus opioids plus tranexamic acid is a more significant combination.
• Women who drive or operate heavy machinery as part of their work. Even mild additive dizziness during the five-day treatment window can be functionally impairing.
• Pregnant women. Pregabalin carries a congenital malformation signal; tranexamic acid in the first trimester for elective reasons is not well-studied.
• Women with a history of pregabalin misuse or dependence.

Should avoid this combination or require specialist review:

• Women with severe renal failure or on dialysis.
• Women currently pregnant and not in an acute hemorrhage situation.
• Women with a personal or family history of thromboembolic events who are also on estrogen therapy, since tranexamic acid carries a thrombosis warning and estrogen further raises thromboembolic risk.

ACOG notes that women with inherited thrombophilias or a personal history of DVT or PE should not use tranexamic acid without hematology review.

The Evidence Gap Women Deserve to Know About

Clinical trial data on this specific drug combination in women is absent. The interaction classification comes from combining the individual pharmacodynamic profiles of each drug, not from a study that enrolled women on pregabalin who were then given tranexamic acid. Women have been historically under-represented in pharmacokinetic and drug-interaction studies. A 2020 analysis in Biology of Sex Differences found that women comprised only 44% of participants in FDA-required drug interaction studies across 86 new molecular entities approved from 2004 to 2018, and female-specific PK analyses were reported in fewer than half of those submissions. The reassurance that "no clinically significant pharmacokinetic interaction exists" is valid, but the data on pharmacodynamic burden in women specifically, taking both drugs at the doses used clinically for HMB and fibromyalgia, does not yet exist.

This matters because the women most likely to receive this combination are also dealing with blood loss, pain, and sleep disruption, all of which compound CNS impairment independently of drug effects.

Tranexamic Acid Drug Interactions: The Broader Picture

Women on tranexamic acid should know it has a broader interaction list beyond pregabalin.

Combining tranexamic acid with hormonal contraceptives (combined oral contraceptive pills, the patch, or the ring) increases thrombotic risk, since both independently promote a procoagulant state. The Lysteda prescribing information specifically warns that women using hormonal contraceptives have an increased risk of thromboembolism, and that tranexamic acid use alongside them adds further risk. This is one of the most clinically important interactions for women.

Tranexamic acid combined with all-trans retinoic acid (tretinoin, used for acne or antiaging) may theoretically increase thrombotic risk based on animal data, though human evidence is thin.

Factor IX complex concentrates and anti-inhibitor coagulant concentrates combined with tranexamic acid raise the risk of thrombosis, a consideration for women with clotting disorders managed with these agents.

No meaningful interaction exists between tranexamic acid and most antidepressants, NSAIDs (though NSAIDs can worsen bleeding independently), or common thyroid medications. Women often ask about the combination with iron supplementation taken for menstrual blood loss: there is no pharmacokinetic or pharmacodynamic concern with that pairing.